LINC 2022: Late-breaking Science Video Collection

Published: 14 June 2022

  • Views:

    Views Icon 2810
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating
View Transcript


Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Faculty Biographies

Michael Lichtenberg

Michael Lichtenberg

Chief Medical Officer and Director of the Angiology Department and Vascular Center

Michael Lichtenberg, MD, FESC is the Chief Medical Officer and Director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany.

Dr. Lichtenberg earned his medical degree from the Heinrich-Heine Medical University of Dusseldorf, and also studied at the Tulane University School of Medicine in New Orleans, Louisiana and the Texas Heart Institute in Houston, Texas.

As esteemed Interventional Angiologist with 20 years of experience in endovascular interventions, Dr. Lichtenberg was elected to serve as Managing Director of the German Society for Angiology in 2017. In 2019, he was elected to serve as the society’s President.

Dr. Lichtenberg’s areas of clinical interest include deep venous intervention, peripheral artery disease, peripheral thrombosis and atherosclerosis.

In addition to his day-to-day work in interventional care, his main interest is the evaluation of new devices, techniques and procedures for the…

View full profile


- Hello. My name is Michael Lichtenberg from Arnsberg Vascular Centre. I'm interventional angiologist practicing in the arterial and venous field for many years now.

Outline of the BioMimics 3D Stent Used in This Study

So this is a very unique stent design. It's a helical stent, which promotes swirling flow. And we know that swirling flow suppresses re-stenosis meaning with this stent, we can definitely work against re-stenosis and therefore it was very interesting to evaluate this swirling flow BioMimics stent in a multicenter prospective registry to see about the efficacy and safety for the stent.


So it was a typical all-comers open registry with a multicenter inclusion meaning we included patients with different disease. There was a very open inclusion criteria catalogue, nearly no exclusion criteria.

Patient Population and Study Design

So we included patients with claudication, critical limb ischemia within the SFA and popliteal segment. And the very interesting thing is that so many centres took part in this trial and included more than 500 patients in a very short time in this registry. So I can say that I'm very proud of this group of physicians who included in this trial. And I really would say thank you as the principal investigator to all these participating centres for this trial.

Key Findings

So we found that the BioMimics stent was highly efficient in patients with short and long SFA and popliteal lesions, including CTOs, meaning patients with complex total occlusions, patients with severe calcification. We found a very high efficiency of the stent even for these most challenging patient cohort.

Take-Home Messages

So one aspect I would like to mention here, we allowed the centres to combine the stent with drug coated balloon angioplasty technique. We found no difference between DCB yes or no in conjunction with the stent, meaning the stent itself was so highly efficient that you don't even need a drug coated balloon. So therefore the conclusion of this registry is that this is a very efficient stent for many indication in patients with claudication and critical limb ischemia.

Next Steps

So the next step is to evaluate the stent even in the whole popliteal segment including popliteal segment two and three, and I'm looking forward to include also patient in such a prospective registry and trial.